Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

Next Previous
Trial Profile

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Soquelitinib (Primary)
  • Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell leukaemia; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Corvus Pharmaceuticals

Most Recent Events

  • 08 Dec 2025 Results presented in the Corvus Pharmaceuticals Media Release.
  • 08 Dec 2025 According to a Corvus Pharmaceuticals media release, company has announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which has taken place in December 6-9, 2025 in Orlando, FL.
  • 20 Mar 2025 According to a Corvus Pharmaceuticals media release, data from this trial presented at the 16th Annual T-Cell Lymphoma Forum

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top